Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12216
Title: Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia.
Authors: Chatterton, Zac;Burke, Daniel;Emslie, Kerry R;Craig, Jeffery M;Ng, Jane;Ashley, David M;Mechinaud, Francoise;Saffery, Richard;Wong, Nicholas C
Affiliation: Cancer and Disease Epigenetics and Department of Paediatrics, University of Melbourne, Melbourne, Australia; current address: Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY; zac.chatterton@mssm.edu.
National Measurement Institute, Sydney, Australia;
Developmental Epigenetics, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia;
Cancer and Disease Epigenetics and Department of Paediatrics, University of Melbourne, Melbourne, Australia;
Andrew Love Cancer Centre, Deakin University, Victoria, Australia;
Children's Cancer Centre, Royal Children's Hospital, Victoria, Australia;
Cancer and Disease Epigenetics and Department of Paediatrics, University of Melbourne, Melbourne, Australia; current address: Ludwig Institute of Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 14-May-2014
Citation: Clinical Chemistry 2014; 60(7): 995-1003
Abstract: DNA methylation biomarkers capable of diagnosis and subtyping have been found for many cancers. Fifteen such markers have previously been identified for pediatric acute lymphoblastic leukemia (ALL). Validation of these markers is necessary to assess their clinical utility for molecular diagnostics. Substantial efficiencies could be achieved with these DNA methylation markers for disease tracking with potential to replace patient-specific genetic testing.We evaluated DNA methylation of promoter regions of TLX3 (T-cell leukemia homeobox) and FOXE3 (forkhead box E3) in bone marrow biopsies from 197 patients classified as leukemic (n = 95) or clear of the disease (n = 102) by MALDI-TOF. Using a single nucleotide extension assay (methylSABER), we tested 10 bone marrow biopsies collected throughout the course of patient chemotherapy. Using reference materials, diagnostic thresholds and limits of detection were characterized for both methods.Reliable detection of DNA methylation of TLX3 and FOXE3 segregated ALL from those clear of disease with minimal false-negative and false-positive results. The limit of detection with MALDI-TOF was 1000-5000 copies of methylated allele. For methylSABER, the limit of detection was 10 copies of methylated TLX3, which enabled monitoring of minimal residual disease in ALL patients.Mass spectrometry procedures can be used to regionally multiplex and detect rare DNA methylation events, establish DNA methylation loci as clinically applicable biomarkers for disease diagnosis, and track pediatric ALL.
Internal ID Number: 24829271
URI: http://ahro.austin.org.au/austinjspui/handle/1/12216
DOI: 10.1373/clinchem.2013.219956
URL: http://www.ncbi.nlm.nih.gov/pubmed/24829271
Type: Journal Article
Subjects: Adolescent
Case-Control Studies
Child
Child, Preschool
DNA Methylation
False Negative Reactions
False Positive Reactions
Female
Forkhead Transcription Factors.genetics
Gene Dosage
Genetic Markers
Homeodomain Proteins.genetics
Humans
Infant
Limit of Detection
Male
Neoplasm, Residual.diagnosis.genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma.diagnosis.drug therapy.genetics
Promoter Regions, Genetic
Reference Standards
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.